Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth [Seeking Alpha]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Seeking Alpha
SNDX's commercial ramp is accelerating, with Revuforj prescriptions up 25%, and management is confident cash reserves will fund operations to profitability. 2026 revenue projections for SNDX range from $245M to $512M, depending on growth scenarios, but risks include reimbursement and competitive shifts. Despite a premium valuation, I remain bullish on SNDX due to rapid sales growth and first-mover advantage, expecting further upside as sales momentum continues. PeopleImages/iStock via Getty Images Thesis For 3Q25, Syndax Pharmaceuticals ( SNDX posted a GAAP EPS loss of –$0.70, which beat estimates by $0.04. Revenue came in at roughly $45.9 million, missing expectations slightly by $2.07 million despite a decent 267% year-over-year increase, which was mainly driven by This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Syndax Announces Participation at the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating [Yahoo! Finance]Yahoo! Finance
- Syndax Pharmaceuticals (NASDAQ:SNDX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SNDX
Earnings
- 11/3/25 - Beat
SNDX
Sec Filings
- 12/1/25 - Form 4
- 11/3/25 - Form 10-Q
- 11/3/25 - Form 8-K
- SNDX's page on the SEC website